The US Food and Drug Administration has granted San Diego-based regenerative-medicine company Cytori Therapeutics, Inc. conditional approval for an Investigational Device Exemption or IDE for a central study dubbed, STAR. The investigation will evaluate Cytori Cell Therapy‘s efficacy as a new solution for impaired hand function in patients with…
News
The right ventricle is extremely critical to the progression of pulmonary hypertension due to its position immediately before the pulmonary artery. It was previously shown the volume of the right ventricle can predict changes in clinically stable…
Although right heart catheterization is an invasive procedure, it can detect changes in right ventricular volume that predict clinical worsening of pulmonary arterial hypertension. A study from the Department of Pulmonary Diseases at VU University Medical Center in Amsterdam, “Signs of Right Ventricular Deterioration in…
A research group from New York Medical College has found a gene that may control pulmonary hypertension severity, as well as the less severe form that occurs in women versus men. The article appeared November 21, 2014, in the journal Molecular Medicine. entitled, “Deletion of STAT5a/b in…
Courtesy of EchoSense Two clinical trials from EchoSense Ltd. are directed toward using lung Doppler signals (LDS) to predict the risk for pulmonary hypertension in patients with systemic sclerosis (SSc). The trials will evaluate the feasibility of identifying pulmonary vessels characteristics using LDS and EchoSense’s processing…
Actelion Pharmaceuticals Ltd., has just announced its has sent the European Medicines Agency (EMA) an application for the centralized Marketing Authorization of selexipag (Uptravi®), indicated for the treatment of pulmonary arterial hypertension (PAH). While the drug’s MAA is pending validation, the company is working…
A recent study entitled “Spectrum of diffuse parenchymal lung diseases with special reference to idiopathic pulmonary fibrosis and connective tissue disease: An eastern India experience,” published in the journal Lung India, compared the clinical spectrum of diffuse parenchymal lung diseases (DPLD) with idiopathic pulmonary fibrosis…
Bayer is sponsoring a long-term observational clinical trial involving patients with pulmonary hypertension or pulmonary arterial hypertension due to scleroderma. The aim of the study is to determine the efficacy, safety, and tolerability of inhaled Ventavis (iloprost, also known as BAYQ6256) in 160 patients with either idiopathic or familial…
Corbus Pharmaceuticals Holdings, Inc. is an emerging drug development company focused on the development and commercialization of Resunab™, the company’s lead product candidate to treat rare and severe life-threatening fibrotic and inflammatory diseases such as scleroderma and cystic fibrosis.
Treating patients with systemic sclerosis (SSc) who have borderline pulmonary arterial hypertension (PAH) is vital to patient health, as life expectancy after a diagnosis of SSc-PAH is only one year. Accordingly, Heidelberg University, along with GlaxoSmithKline, initiated a clinical trial to investigate “Early Treatment…
Clinicians, scientists, and researchers have acknowledged an association between systemic sclerosis (SSc) and pulmonary arterial hypertension, and have even created the disease category “SSc-PAH,” or SSc-related PAH. This category of PAH is remarkably similar to heritable PAH, yet the basis for the similarity has remained unknown. In an effort…
Image Courtesy of TomTec Imaging Systems TomTec Imaging Systems, a Munich-based company specializing in medical imaging and information management software with a focus on ultrasound technologies, has just announced its groundbreaking 4D RV-Function© software that allows extensive assessment of the right ventricle (RV) of the heart. This diagnostic and…
